DSGN Design Therapeutics Inc Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization
Backed by solid capital, Design Therapeutics (DSGN) focuses on creating small-molecule GeneTACs to manage gene expression in neurodegeneration, although a sustainable advantage will emerge following tests. The share price history on GURU.Markets with the 0.00 metric highlights a lack of debt and success in Friedreich's ataxia therapy. Design Therapeutics (DSGN) is developing innovative drugs to combat hereditary pathologies using a unique correction method that does not modify DNA.
Comprehensive metric breakdowns and analytics for designtx.com (DSGN)
- current price and projected stock value:
- market capitalization data:
- book value of equity indicators:
- company total debt and liquidity indicators:
Total Debt to Capital Design Therapeutics|DSGN - Long-Term Debt to Capital Coefficient|Short-Term Debt to Capital Design Therapeutics, Inc.|DSGN - Company Cumulative Debt|Debt to Book Capitalization Ratio Design Corp|DSGN - Company Long-Term Loans and Borrowings|Company Short-Term Debts Design Therapeutics|Quick Liquidity designtx.com
- net income and valuation multiples indicators:
DSGN - Profit After Tax|Projected Future Earnings Design Therapeutics|DSGN - Market Cap to Earnings|Projected Price to Earnings Design Therapeutics|DSGN - PEG Multiple|Enterprise Value to EBITDA Ratio Design Corp|DSGN - Company profit before taxes, interest and amortization|Net earnings per share (EPS TTM) Design Therapeutics|DSGN - Net earnings per share for the last four quarters|Quarterly EPS earnings growth designtx.com|DSGN - Net earnings per share growth this year|Net earnings per share growth forecast for next year Design Therapeutics
Initial company analysis:DSGN (Design Pharma)
For the biotech sector, this indicator serves as a tool for comparing total asset value with operational efficiency. By analyzing the EV/EBITDA multiple chart, an investor assesses the ratio of market capitalization plus debt to earnings before depreciation and amortization. In the case of Design Therapeutics (DSGN), the metric reflects speculative value due to its dependence on clinical trial outcomes. Single-product risk renders this indicator volatile, turning it into a marker of market expectations.
Key competitors
EV/EBITDA Multiple TEM (tempus.com)|Enterprise Value to EBITDA Multiple Qiagen Corp|IONS - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|RGEN (repligen.com) - Enterprise Value to Operating Income Before Depreciation|RNA (Avidity Biosciences, Inc.) - Enterprise Value to EBITDA Ratio|CRISPR Therapeutics Inc - Business Value to Operating Income Before Depreciation|Enterprise Value to EBITDA Ratio WGS|RARE (Ultragenyx Corp) - Enterprise Value to Operating Income Before Depreciation Ratio|EV/EBITDA Multiple BEAM|SRPT (sarepta.com) - Business Value to Operating Income Before Depreciation|EV/EBITDA Multiple TWST (Twist Bioscience, Inc.)|10x Genomics Inc (TXG) - Company Value to EBITDA|NTLA - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Business Value to Operating Income Before Depreciation STOK (Stoke Corp)|BLFS: EV/EBITDA Multiple|wavelifesciences.com (WVE) - EV/EBITDA Multiple|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Maze Therapeutics|Sionna Therapeutics, Inc. - Company Value to Operating Income Before Depreciation Ratio|EV/EBITDA Multiple PRME|TSHA - Company Value to EBITDA|uniQure N.V. - Enterprise Value to EBITDA Ratio|EV/EBITDA Multiple meiragtx.com MGTX|RGNX: Enterprise Value to EBITDA Ratio|Solid Biosciences Inc - Enterprise Value to Operating Income Before Depreciation Ratio|OCGN: EV/EBITDA Multiple|PACB - Total Company Value to Operating Income Before Depreciation Ratio|BNTC (Benitec Biopharma Inc.) - EV/EBITDA Multiple|Enterprise Value to EBITDA Ratio rocketpharma.com (RCKT)|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization 4D Molecular Therapeutics, Inc. (FDMT)|Total Company Value to Operating Income Before Depreciation Ratio lexeotx.com|EV/EBITDA Multiple KRRO (Korro Bio)|EDIT: Enterprise Value to Operating Income Before Depreciation|SLN - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Total Company Value to Operating Income Before Depreciation Ratio ProQR Therapeutics N.V. PRQR|CDXS: EV/EBITDA Multiple|Enterprise Value to EBITDA Multiple Sangamo Therapeutics Inc. SGMO|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Nautilus Biotechnology, Inc.|Enterprise Value to Operating Income Before Depreciation MGX (Metagenomi Therapeutics)|EV/EBITDA Multiple DTIL|generationbio.com - Enterprise Value to Operating Income Before Depreciation|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Boundless Bio BOLD|XCUR: Enterprise Value to Operating Income Before Depreciation|Celsion Corporation - EV/EBITDA Multiple|PHIO - EV/EBITDA Multiple|MBIO: EV/EBITDA Multiple|Enterprise Value to Operating Income Before Depreciation RNAZ|BNGO (Bionano Genomics Inc.) - EV/EBITDA Multiple|Company Value to EBITDA Applied DNA Sciences Inc APDN|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Bluebird Bio (BLUE)|Total Company Value to Operating Income Before Depreciation Ratio immunoprecise.com|EV/EBITDA Multiple OMGA (Omega Therapeutics)|Total Company Value to Operating Income Before Depreciation Ratio singulargenomics.com (OMIC)|Regulus Therapeutics Inc. - EV/EBITDA Multiple|Enterprise Value to EBITDA Multiple Syros Pharmaceuticals Inc. (SYRS)|Codex DNA (TBIO) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Enterprise Value to Operating Income Before Depreciation TCON|Enterprise Value to EBITDA Ratio UBX
